Fed. Circ. Says Sandoz Biosimilars Don't Step On Amgen IP
The Federal Circuit cleared Novartis' Sandoz division of patent infringement Wednesday over its biosimilar versions of Amgen's chemotherapy companion drugs Neupogen and Neulasta, upholding a lower court ruling....To view the full article, register now.
Already a subscriber? Click here to view full article